Regencell Investors Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 40 minutes ago
0mins
Source: Globenewswire
- Lawsuit Deadline: Investors must file a lead plaintiff motion by June 23, 2026, to participate in the class action against Regencell, which involves those who purchased the company's securities between October 28, 2024, and October 31, 2025.
- Market Volatility Impact: On October 31, 2025, Regencell received a subpoena from the U.S. Department of Justice due to market volatility, resulting in a stock price drop of $3.09, or 18.56%, on November 3, 2025, which adversely affected investors' financial positions.
- Expected Legal Costs: The company anticipates incurring significant legal fees and other expenses related to the investigation, potentially requiring payments exceeding its insurance coverage, which could strain its financial health.
- False Statements Allegations: The class action alleges that the company failed to disclose risks of market manipulation and regulatory scrutiny during the class period, exposing investors to substantial financial risks and harming their interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regencell Investors Class Action Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by June 23, 2026, to participate in the class action against Regencell, which involves those who purchased the company's securities between October 28, 2024, and October 31, 2025.
- Market Volatility Impact: On October 31, 2025, Regencell received a subpoena from the U.S. Department of Justice due to market volatility, resulting in a stock price drop of $3.09, or 18.56%, on November 3, 2025, which adversely affected investors' financial positions.
- Expected Legal Costs: The company anticipates incurring significant legal fees and other expenses related to the investigation, potentially requiring payments exceeding its insurance coverage, which could strain its financial health.
- False Statements Allegations: The class action alleges that the company failed to disclose risks of market manipulation and regulatory scrutiny during the class period, exposing investors to substantial financial risks and harming their interests.
See More
Regencell Bioscience Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd., seeking damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting investor concerns over potential risks associated with the company.
- Allegations of False Statements: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose the company's vulnerability to market manipulation, which exposed investors to significant financial risks and reflects serious governance deficiencies.
- Legal Consequences Risk: Due to the aforementioned false statements, Regencell faces heightened risks of regulatory and governmental scrutiny, which could lead to significant legal, financial, and reputational harm, further exacerbating investor concerns.
- Investor Action Call: Investors are encouraged to apply to be lead plaintiffs by June 23, 2026, to share in any potential recovery from the lawsuit, indicating a strong emphasis on protecting investor rights.
See More
RGC Investors Alert: Lead Plaintiff Selection Deadline Approaches
- Lead Plaintiff Deadline: RGC investors must file a motion by June 23, 2026, to seek appointment as lead plaintiff in the class action, ensuring their representation in light of an 18.56% stock decline triggered by a DOJ subpoena, which could significantly impact their losses.
- Role of Lead Plaintiff: Under the Private Securities Litigation Reform Act of 1995, the court appoints a lead plaintiff to represent all shareholders' interests, directing case strategy and selecting counsel, which is crucial for protecting investor rights, especially amid substantial losses.
- Absent Member Rights: Investors who purchased RGC securities during the class period but do not apply for lead plaintiff status retain the right to participate in any recovery, meaning they do not need to take action before the deadline to preserve their rights.
- Investor Consultation Services: Levi & Korsinsky, LLP offers consultation to help investors assess their eligibility for lead plaintiff status, particularly for those who have incurred significant losses during the class period, ensuring they can effectively engage in the litigation process.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action and potentially receive compensation without any out-of-pocket costs.
- Choosing Legal Representation: The firm emphasizes the importance of selecting qualified counsel with a proven track record, noting that many firms issuing notices lack the necessary experience and may only act as intermediaries rather than litigators.
- Case Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation risks and regulatory scrutiny, resulting in significant financial losses.
- Historical Achievements: Rosen Law Firm has previously secured the largest securities class action settlement against a Chinese company and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its strong capabilities and influence in the securities litigation field.
See More
Class Action Lawsuits Filed for Multiple Companies
- LKQ Corporation Lawsuit: A class action has been filed on behalf of LKQ shareholders for the period from February 27, 2023, to July 23, 2025, alleging that the company failed to disclose significant risks related to customer losses and declining market share, potentially misleading investors and impacting future financial performance.
- Regencell Bioscience Lawsuit: Shareholders of Regencell, during the class period from October 28, 2024, to October 31, 2025, have initiated a class action, claiming the company did not disclose risks of market manipulation and the resulting financial exposure to investors, which could lead to regulatory scrutiny and legal repercussions.
- Globant Lawsuit: A class action has been filed for Globant shareholders for the period from February 15, 2024, to August 14, 2025, alleging that the company failed to reveal decreasing demand in Latin America and wage freezes, misleading investors about the company's prospects and potentially damaging market trust.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind affected investors to seek legal advice to participate in these class actions, highlighting the importance of legal protections for investors' rights.
See More
Investors Alert: Class Action Lawsuit Deadlines
- Lawsuit Overview: Holzer & Holzer LLC reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited, alleging undisclosed market manipulation risks from October 2024 to October 2025, with a lead plaintiff application deadline of June 23, 2026.
- SES AI Lawsuit: A class action lawsuit against SES AI Corporation claims false statements made between January 2025 and March 2026, urging investors to apply for lead plaintiff status by June 26, 2026, to protect their legal rights.
- POET Lawsuit: The class action against POET Technologies Inc. alleges undisclosed tax status issues from April 2026, with a deadline of June 29, 2026, for investors to apply as lead plaintiffs to secure their position in the case.
- Law Firm Background: Holzer & Holzer LLC, established in 2000, has focused on representing shareholders, recovering hundreds of millions for victims of corporate misconduct, highlighting its expertise and influence in securities litigation.
See More
Regencell Investors Class Action Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by June 23, 2026, to participate in the class action against Regencell, which involves those who purchased the company's securities between October 28, 2024, and October 31, 2025.
- Market Volatility Impact: On October 31, 2025, Regencell received a subpoena from the U.S. Department of Justice due to market volatility, resulting in a stock price drop of $3.09, or 18.56%, on November 3, 2025, which adversely affected investors' financial positions.
- Expected Legal Costs: The company anticipates incurring significant legal fees and other expenses related to the investigation, potentially requiring payments exceeding its insurance coverage, which could strain its financial health.
- False Statements Allegations: The class action alleges that the company failed to disclose risks of market manipulation and regulatory scrutiny during the class period, exposing investors to substantial financial risks and harming their interests.
See More
Regencell Bioscience Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd., seeking damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting investor concerns over potential risks associated with the company.
- Allegations of False Statements: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose the company's vulnerability to market manipulation, which exposed investors to significant financial risks and reflects serious governance deficiencies.
- Legal Consequences Risk: Due to the aforementioned false statements, Regencell faces heightened risks of regulatory and governmental scrutiny, which could lead to significant legal, financial, and reputational harm, further exacerbating investor concerns.
- Investor Action Call: Investors are encouraged to apply to be lead plaintiffs by June 23, 2026, to share in any potential recovery from the lawsuit, indicating a strong emphasis on protecting investor rights.
See More
RGC Investors Alert: Lead Plaintiff Selection Deadline Approaches
- Lead Plaintiff Deadline: RGC investors must file a motion by June 23, 2026, to seek appointment as lead plaintiff in the class action, ensuring their representation in light of an 18.56% stock decline triggered by a DOJ subpoena, which could significantly impact their losses.
- Role of Lead Plaintiff: Under the Private Securities Litigation Reform Act of 1995, the court appoints a lead plaintiff to represent all shareholders' interests, directing case strategy and selecting counsel, which is crucial for protecting investor rights, especially amid substantial losses.
- Absent Member Rights: Investors who purchased RGC securities during the class period but do not apply for lead plaintiff status retain the right to participate in any recovery, meaning they do not need to take action before the deadline to preserve their rights.
- Investor Consultation Services: Levi & Korsinsky, LLP offers consultation to help investors assess their eligibility for lead plaintiff status, particularly for those who have incurred significant losses during the class period, ensuring they can effectively engage in the litigation process.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action and potentially receive compensation without any out-of-pocket costs.
- Choosing Legal Representation: The firm emphasizes the importance of selecting qualified counsel with a proven track record, noting that many firms issuing notices lack the necessary experience and may only act as intermediaries rather than litigators.
- Case Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation risks and regulatory scrutiny, resulting in significant financial losses.
- Historical Achievements: Rosen Law Firm has previously secured the largest securities class action settlement against a Chinese company and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its strong capabilities and influence in the securities litigation field.
See More
Class Action Lawsuits Filed for Multiple Companies
- LKQ Corporation Lawsuit: A class action has been filed on behalf of LKQ shareholders for the period from February 27, 2023, to July 23, 2025, alleging that the company failed to disclose significant risks related to customer losses and declining market share, potentially misleading investors and impacting future financial performance.
- Regencell Bioscience Lawsuit: Shareholders of Regencell, during the class period from October 28, 2024, to October 31, 2025, have initiated a class action, claiming the company did not disclose risks of market manipulation and the resulting financial exposure to investors, which could lead to regulatory scrutiny and legal repercussions.
- Globant Lawsuit: A class action has been filed for Globant shareholders for the period from February 15, 2024, to August 14, 2025, alleging that the company failed to reveal decreasing demand in Latin America and wage freezes, misleading investors about the company's prospects and potentially damaging market trust.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind affected investors to seek legal advice to participate in these class actions, highlighting the importance of legal protections for investors' rights.
See More
Investors Alert: Class Action Lawsuit Deadlines
- Lawsuit Overview: Holzer & Holzer LLC reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited, alleging undisclosed market manipulation risks from October 2024 to October 2025, with a lead plaintiff application deadline of June 23, 2026.
- SES AI Lawsuit: A class action lawsuit against SES AI Corporation claims false statements made between January 2025 and March 2026, urging investors to apply for lead plaintiff status by June 26, 2026, to protect their legal rights.
- POET Lawsuit: The class action against POET Technologies Inc. alleges undisclosed tax status issues from April 2026, with a deadline of June 29, 2026, for investors to apply as lead plaintiffs to secure their position in the case.
- Law Firm Background: Holzer & Holzer LLC, established in 2000, has focused on representing shareholders, recovering hundreds of millions for victims of corporate misconduct, highlighting its expertise and influence in securities litigation.
See More
